Oprelvekin

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameOprelvekin
Drug Alias NameInterleukin-11 (Pfizer)奥普瑞白介素奥普瑞白介素-11oprelvekinaoprelvekinum +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionThrombopoiesis stimulantsInterleukin 11 receptor alpha stimulants
TargetsInterleukin 11 receptor alpha
Therapy Area/IndicationsThrombocytopeniavon Willebrand DiseasesHemophilia A +[5] 
Global Approved IndicationsThrombocytopenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1997/11/25
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth LlcUniversity Of PittsburghThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsN/A
Inactive IndicationsThrombocytopeniavon Willebrand DiseasesHemophilia A +[5] 

Other Information

ATC CodeL03AC02
Related LinksWikipediaDrugBankKEGG